Wegovy HD: What Is the New High-Dose Wegovy 7.2 mg?

Wegovy HD received FDA approval on March 19, 2026. It is a higher-dose formulation of the same semaglutide injection that has been available since 2021, but at 7.2 mg rather than the standard 2.4 mg.

For patients who have been on Wegovy and want to understand what this new dose means, here is a clear overview.

What is Wegovy HD?

Wegovy HD contains semaglutide 7.2 mg and is administered as a once-weekly subcutaneous injection, the same delivery method as standard Wegovy. The molecule, the mechanism, and the injection format are all identical to existing Wegovy. The difference is the dose.

Standard Wegovy doses:

• 0.25 mg (starting dose)
• 0.5 mg
• 1 mg
• 1.7 mg
• 2.4 mg (maintenance dose)
• 7.2 mg (new HD dose, for patients who need more)

What weight loss does Wegovy HD produce?

Clinical trial results showed that patients taking the 7.2 mg dose achieved an average of approximately 21% body weight loss. About one in three patients on Wegovy HD lost 25% or more of their body weight.

For comparison, the standard 2.4 mg Wegovy produces an average of around 15–17% body weight loss in clinical trials.

That is a meaningful difference for patients who have been on standard Wegovy but feel they have not reached their weight loss goal.

Who is Wegovy HD for?

Wegovy HD is not a first-line option. It is intended for adults who:

• are already on GLP-1 therapy and tolerating it well
• have obesity (BMI ≥ 30) or overweight with a weight-related comorbidity
• need additional weight loss beyond what the standard dose is producing

Your prescribing doctor will determine whether Wegovy HD is appropriate for your situation. Do not adjust your dose without medical guidance.

How does Wegovy HD differ from CagriSema or Retatrutide?

Wegovy HD is an established molecule at a higher dose. It is not a new drug.

Drugs like CagriSema (in FDA review) and Retatrutide (in Phase 3) use different mechanisms and have shown higher average weight loss in trials. However, those drugs are not yet approved. Wegovy HD is available now, through the same pharmacy channels as existing Wegovy.

What are the side effects?

Side effects for Wegovy HD are consistent with the existing semaglutide class:

• nausea (most common, especially early)
• diarrhea
• vomiting
• constipation
• fatigue

At higher doses, gastrointestinal side effects may be more pronounced, particularly during dose escalation. Starting low and escalating slowly helps most patients manage the transition.

How to track Wegovy HD

If you switch to the higher dose, your weekly pattern will shift. Appetite suppression, side effect timing, and energy levels may all change compared to your previous dose. Keeping a consistent log through the transition makes it much easier to tell whether the new dose is settling in or whether something needs adjusting.

WeightEasy tracks dose changes, weekly injection logs, symptom patterns, and weight trends in one place, which is useful when you are moving between dose tiers.

Final takeaway

Wegovy HD is the same weekly semaglutide injection at a higher dose (7.2 mg), FDA approved in March 2026. It produces stronger average weight loss than the standard 2.4 mg dose and is designed for patients who need more from their GLP-1 therapy. Talk to your doctor about whether it is right for your situation.

Consult your healthcare provider before starting, adjusting, or stopping any medication.

Sources

• FDA approval announcement: Wegovy HD, March 19, 2026
• Wegovy FDA approval history: drugs.com/history/wegovy.html
• Phase 3 clinical trial data: Lilly/Novo Nordisk press releases and NEJM publications